Companies Dominating the Immuno-oncology Treatment Devices and Drugs Landscape
- Merck & Co.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bristol-Myers Squibb
- Roche (Genentech)
- Novartis
- Johnson & Johnson
- Pfizer
- AstraZeneca
- Gilead Sciences
- Amgen
- Sanofi
- Takeda Pharmaceutical
- Daiichi Sankyo
- Eli Lilly
- GSK
- BeiGene
- Hengrui Pharma
- Celltrion
- CSL (Seqirus)
- Dr. Reddy’s Laboratories
- Pharmaniaga
Key organizations in the immuno-oncology treatment devices and drugs market are making contributions towards the expansion by adopting numerous feasible strategies. The global market is witnessing dominance in terms of Europe and the U.S.-based firms, such as Merck, BMS, Roche, that are leveraging checkpoint inhibitors. Besides acquisitions and partnerships, such as Sanofi and Regeneron, have amplified innovation in cell and gene therapies. Furthermore, AI-based drug discovery with the integration of authentic evidence is the key differentiator for future growth.
Some of the prominent players are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of immuno-oncology treatment devices and drugs is evaluated at USD 111.5 billion.
Immuno-oncology Treatment Devices and Drugs Market size was valued at USD 98.9 billion in 2024 and is projected to reach USD 380.6 billion by the end of 2037, rising at a CAGR of 13.2% during the forecast period, i.e., 2025-2037.
The North America immuno-oncology treatment devices and drugs market is predicted to capture the largest share of 48.8% over the forecasted timeframe.
Merck & Co., Bristol-Myers Squibb, Roche (Genentech), Novartis, Johnson & Johnson, Pfizer, AstraZeneca, Gilead Sciences, Amgen, Sanofi, Takeda Pharmaceutical, Daiichi Sankyo, Eli Lilly, GSK, BeiGene, Hengrui Pharma, Celltrion, CSL (Seqirus), Dr. Reddy’s Laboratories, Pharmaniaga.
